Table 3. Introduction and recurrent costs per dose and per fully immunized girl in the Zimbabwe human papillomavirus vaccination project, 2014–2015.

Cost category	Financial cost, US$				Economic cost, US$
	Total	Per dosea	Per fully immunized girlb		Total	Per dosea	Per fully immunized girlb
Introduction costsc	120 981	10.43	21.14		214 637	18.50	37.50
Recurrent costsd	108 163	9.33	18.90		307 309	26.49	53.69
Total costs	229 144	19.76	40.03		521 946	45.00	91.19
Total costs (without vaccine and vaccine-related suppliese)	228 981	19.74	40.00		463 242	39.94	80.93

HPV: human papillomavirus; US$: United States dollars.

^a Total number of doses delivered: 11 599.

^b Total number of fully immunized girls: 5724.

^c Introduction costs are initial investments that are expected to last longer than 1 year, and include the activity categories of microplanning, training, and sensitization and information materials.

^d Recurrent costs are expected to last less than 1 year. This includes activity categories of vaccines (i.e. cost of vaccine, syringe and vaccine carriers and cold packs) (only included in economic cost) and vaccine-related supplies of safety boxes, and cotton (included in both financial and economic costs), service delivery, supervision, and monitoring and evaluation. Based on the WHO Cervical Cancer Prevention and Control Costing tool user guide.¹⁸

^e Vaccine procurement and injection supplies includes the procurement and distribution of vaccine, syringes, safety boxes, vaccine carriers and cold packs, and cotton. Note that for specific cost calculations, the financial cost includes safety boxes and cotton; economic cost additionally includes the cost of the vaccine including freight and transportation, vaccine carriers and cold packs, and syringes.

Note: We collected costs in current prices from 2014, 2015 and 2016, adjusted for inflation to 2016 US$ using the Zimbabwe consumer price index.²⁰